Insights

EP. 1: Treatment Goals and Recommended Frontline Options for CLL
EP. 2: Key Considerations for Individualizing Therapy in CLL
EP. 3: Data on Limited-Duration Therapy in CLL with MRD Testing
EP. 4: Role of BTK Inhibitor Monotherapy in CLL Frontline Setting
EP. 5: New and Pipeline BTK Inhibitors in CLL at the Frontline
EP. 6: CAPTIVATE Study BTK Inhibitors With BCL2 Inhibitors in CLL
EP. 7: Venetoclax + Obinutuzumab: for Combination Therapy
EP. 8: Second-Line Therapy in CLL: RESONATE Trial Data
EP. 1: Advancements in Treatment and Management of HER2-Positive Early Breast Cancer: Introduction and the APHINITY Trial
EP. 2: Disease-Free Survival and the KATHERINE Study
EP. 3: Review of the ExteNET Trial and the TRAIN-2 Trial
EP. 4: Agents or Regimens Moving from Metastatic to Early Stage
EP. 5: Role of Biosimilars in Breast Cancer
EP. 6: Subcutaneous Combination Therapy With the FeDeriCa Study
EP. 7: Comparison of IV vs SQ Dosing and Patient Factors
EP. 8: Barriers for Novel Agents
EP. 9: Pharmacists’ Role for Transitioning from IV to SQ
EP. 10: Telehealth During COVID-19 Pandemic
EP. 11: Influence of SQ and COVID-19 on Therapy
EP. 12: Future Therapies in Breast Cancer and Final Thoughts
EP. 1: NCCN Recommendations: Frontline CLL Treatment Options
EP. 2: Front-Line Therapy Decision Criteria
EP. 3: Limited-Duration Therapy Based on MRD Testing
EP. 4: Newly Diagnosed CLL: BTK Inhibitor Monotherapy
EP. 5: Developing Clinical Trials for Newly Diagnosed Disease
EP. 6: First-Line Therapy for Treatment-Naïve Patients
EP. 7: BTK Inhibitor Toxicity Management
EP. 8: Oral Oncolytics Versus Intravenous: Safety and Efficacy
EP. 9: Oral Therapy Adverse Events
EP. 10: Intravenous Versus Oral Delivery: Medical Benefits
EP. 11: Pharmacy-Led Oral Chemotherapy Management Programs
EP. 12: Optimizing Success for Community Physicians
EP. 13: Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia
EP. 14: Experts Discuss Treatment Considerations for Chronic Lymphocytic Leukemia
EP. 1: Myxedema Coma Awareness and Background for Pharmacists
EP. 2: Complexity in the Pharmacy Preparation of Lyophilized Levothyroxine Formulations
EP. 3: Recommendations for Medication Preparation in the Pharmacy
EP. 4: Opportunities for Ready to Use RTU Formulations for Hospital Pharmacists
EP. 1: Overview of Coronary and Peripheral Artery Disease
EP. 2: Primary Prevention for CAD/PAD
EP. 3: Secondary Prevention for CAD/PAD
EP. 4: The Role of Combined Antiplatelet Therapy
EP. 5: Who Is at Increased Risk of CAD/PAD?
EP. 6: Phase 3 COMPASS Trial Overview
EP. 7: Antithrombotic Therapy: Bleeding Adverse Event Defined
EP. 8: New Therapy Data: Guideline Implementation Delays
EP. 9: Experience With Anticoagulant Interchangeability
EP. 10: The Importance of CAD/PAD Education
EP. 11: The Future of CAD/PAD Management
EP. 12: Insights: Experts Discuss Importance of CAD/PAD Management
EP. 13: The Effect of CAD/PAD on Patient Quality of Life
EP. 1: Prevalence and Pathophysiology of Chemo-Induced Nausea & Vomiting
EP. 2: Distinct Types of Chemo-Induced Nausea & Vomiting
EP. 3: Guidelines and Patient Factors Impact on Treatment of CINV
EP. 4: Various Treatments and Doses Used for Prophylaxis of CINV
EP. 5: Economic Burden of Chemo-Induced Nausea and Vomiting
EP. 6: Impact of CINV on Quality of Life
EP. 7: Safety and Efficacy of Treatment Options for CINV
EP. 8: Ancillary Treatment Options for Chemo-Induced Nausea and Vomiting
EP. 9: Providing Early and Appropriate Management of CINV
EP. 10: Patient Factors to Consider for the Therapy of CINV
EP. 11: The Role of Pharmacists in Evaluating the CINV Therapy
EP. 12: Multidrug Therapy and Unmet Needs for CINV